- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OPTIMA MEDICAL INNOVATIONS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,908 | +1,47 % | AURORA CANNABIS INC: Ruhe vor dem nächsten Impuls | ||
| CANOPY GROWTH | 0,931 | -0,11 % | CANOPY GROWTH CORPORATION: Struktur vor Impuls | ||
| TILRAY BRANDS | 4,685 | +1,52 % | Tilray Brands stock is in a freefall: key reasons and what next | ||
| ABBOTT LABORATORIES | 71,56 | -0,39 % | Abbott Laboratories Stock: Analyst Estimates & Ratings | ||
| SINOPHARM | 2,009 | -0,64 % | Reed Sinopharm Exhibitions (RSE): PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou | 860+ exhibitors from 26 countries and regions across 70,000 sqmClose to 50 new product launches, including global and China debuts295 product submissions and 19 engineer nominations for the... ► Artikel lesen | |
| AMARIN | 12,600 | -0,79 % | Amarin Corporation plc: Amarin Reports 2026 First Quarter Financial Results | Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,715 | +1,16 % | Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results | ||
| BRIDGEBIO PHARMA | 59,50 | +5,95 % | BridgeBio Pharma, Inc.: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 | - Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified... ► Artikel lesen | |
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| AURINIA PHARMACEUTICALS | 13,570 | -0,40 % | Aurinia Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| ARGENT BIOPHARMA | 0,015 | 0,00 % | ARGENT BIOPHARMA LIMITED: Final Director's Interest Notice - GH | ||
| CENTR BRANDS | 0,019 | 0,00 % | Centr Brands Corp (2): Centr Brands arranges $50,000 debenture financing | ||
| LABORATORIOS FARMACEUTICOS ROVI | 59,95 | -2,44 % | Rovi Q1 2026: Margen steigen, doch hohe F&E-Investitionen belasten den Gewinn | ||
| AVECHO BIOTECHNOLOGY | 0,007 | +16,67 % | AVECHO BIOTECHNOLOGY LIMITED: Change of Director's Interest Notice x3 | ||
| HERON THERAPEUTICS | 0,795 | -3,29 % | Heron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance | Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF- (+27%) and APONVIE- (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter... ► Artikel lesen |
OPTIMA MEDICAL INNOVATIONS CORP gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTIMA MEDICAL INNOVATIONS CORP finden Sie auf Wallstreet Online.